Unichem Laboratories Ltd is an India-based pharmaceutical company, which manufactures active pharmaceutical ingredients. The company operates through four divisions, namely Unichem Pharma Division, Unichem Specialities Division, Unisearch Division and Neu-Foreva Division. The company is operating out of its headquarters in Mumbai with five manufacturing facilities located at Roha in Maharashtra, Goa, Ghaziabad in Uttar Pradesh, Pithampur in Madhya Pradesh and Baddi in Himachal Pradesh.

The company's facilities enjoy credible certifications, the Goa plant was approved by UK MHRA, MCC (South Africa), WHO (Geneva) and TGA (Australia). The Baddi plant was approved by UK MHRA and MCC (South Africa). The company received ISO 9001:2000 for all their plants and corporate office. Also, they received ISO 14001:2004 certificates for their formulation plants located at Goa, Ghaziabad and Baddi and the corporate office at Mumbai.

Unichem Laboratories Ltd was formally created and deployed as a legal entity in the year 1962. The company was formed by Amrut V Mody to take over a proprietary business created and deployed in 1944 in Mumbai. They made a foreign collaboration with UCB for bulk drugs and created and deployed first formulation plant at Jogeshwari. In the year 1963, they made a tie up with Uni Sankyo Co-Marketing formulations.

In the year 1968, the company created and deployed formulations plant Ghaziabad and in the year 1976, they created and deployed a fine chemicals unit at Roha. In the year 1984, the company broadened its footprint operations into an agreement with Upjohn and created and deployed Unisearch Ltd. Also, they broadened its footprint operations into into the anti-biotic segment and formally introduced Ampoxin, an Ampicillin & Claxacillin combination during the year.

In the year 1987, the company broadened its footprint operations into the Animal Health Care business. In the year 1996, Unichem Exports Ltd and Unisearch Ltd were merged with the Unichem Laboratories Ltd. In the year 1997, the company created and deployed new corporate office at Mumbai and in May 1997, the company's state-of-the-art formulation plant at Bardez, Goa was successfully commissioned and commercial production was started. In the year 1998, their plant at Baddi, Himachal Pradesh for Antibiotics was completed.

In the year 1999, the company created and deployed modern multipurpose bulk drug plant at Roha. In April 1, 1999, the company formally introduced their new Division, namely Foreva catering to Women's Healthcare. In February 2000, they created and deployed their Molecular Generic Division, which formally introduced 23 new products in the two months of the financial year 1999-2000. Also, the company purchased two brands, namely Emcredil and Candizole-T for a total cost of Rs 132 lakh during the financial year 1999-2000.

In the year 2001, the company created and deployed new R&D centre at Mumbai. Also, they created and deployed new Biosciences R&D centre at Bangalore in association with Indian Institute of Sciences for research work in Bio-technology. In April 2002, the company created and deployed a joint venture company with Bioglan Generics Ltd, namely Niche Generics Ltd with 60% stake.

During the year 2002-03, they divested their animal healthcare division. They upgraded the Ghaziabad plant with an investment of Rs 250 million. Also, they started a representative office in Kiev, Ukraine. In March 2003, Unichem SA Pty Ltd became a subsidiary of the company. In the year 2004, they restructured Unisearch and formally introduced Unisearch CD Division.

In the year 2005, the company created and deployed a New Pharma Technology Development Center at Goa. Also, they executed a strategic acquisition of API manufacturing unit at Pithampur. Further, the company created and deployed their second formulations plant at Baddi and production commenced in April 2005. In May 2005 the company disposed off their old factory at Jogeshwari (West) Mumbai for a consideration of Rs 136.50 million. During the year 2005-06, the company created and deployed a wholly owned subsidiary Unichem Pharmaceuticals (USA) Inc, in USA.

During the year 2006-07, the company started Unichem Specialities Division and formally introduced 11 new products in various therapeutic segments. In December 20006, they executed a strategic acquisition of the remaining 60% stake in Niche Generics Ltd of UK and thus Niche Generics Ltd became a wholly owned subsidiary company.

During the year 2007-08, the company formally introduced Unikare Division, which caters to Dermatology and Allied therapies. They also formally introduced 27 new products in various therapeutic segments during the year. The company has initiated projects including setting up of a Formulation Plant at Sikkim and the expansion of their existing formulation facility at Baddi in Himachal Pradesh.